← Diabetes Connections | Type 1 Diabetes
Diabetes Connections | Type 1 Diabetes
In the News... New drug tested to prevent type 1, twiist pump integrates with Eversense CGM, Dexcom U is back, and more!
00:05:29
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new Austrailian study aims to prevent type 1, the new twiist pump will integrate with Eversnse CGM as well as Libre, diabetes deaths are...
Loading summary
Transcript1 lines
- [00:00]
A
Foreign hello and welcome to Diabetes Connections in the News. I'm Stacey Sims and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. Our top story, A world first human trial of a drug designed to treat the underlying cause of type one has begun in Australia. The drug is designed to retrain the immune system so it no longer attacks the insulin producing cells known as beta cells. It's given as an injection under the skin. If effective, these researchers say the drug will initially be given to patients with type 1 as soon as possible after diagnosis. But eventually, if screening programs can be developed, it may be possible to prevent the progression of the disease altogether. They say this is a very small study. We're very early here. About 36 participants will test the safety of the drug to start Deaths from diabetes in the US have fallen to some of the lowest rates in years. New preliminary figures from the CDC reversing a surge in mortality that was seen during the COVID 19 pandemic. Death rates from diabetes peaked in 2021. The CDC says the link between COVID 19 and diabetes may be to blame for that increase. Research shows the pandemic may have also made it harder for Americans to properly manage the disease, ranging from interruptions to physical activity to problems with routine medical care diagnosing and treating diabetes. Big news for Eversense cgm, the world's first and only one year continuous glucose monitor. They have the first pump partner, Sequel. Medtech says the Twist pump will integrate with Senseonics ever since 365 SQL and Sensonics say they have already started their work to integrate the latest generation implantable sensor with Twist. They expect to make the integrated offering available in the third quarter of this year. This is the second CGM integration for Sequel. They announced they would be partnering with Abbott and their Freestyle Libre platform earlier this year. This week we also got a peek at the packaging and delivery of the Twist as the first people posted about wearing it. We'll follow up and learn more about this newest insulin pump in the US in the next couple of weeks. Medtronic announces the FDA approval of the Simplera Sync sensor for use with the MiniMed 780G system. The Simplera Sync is a disposable all in one sensor that requires no finger sticks. It is the company's newest addition to its CGM portfolio. A limited launch of the Simplara Sync sensor will begin in the US in the fall of 2020. The MiniMed 780G system can be used now with the Guardian 4 sensor front office changes coming to Insulet, the former head of Johnson and Johnson's worldwide medtech business. Ashley McAvoy will take over as president and CEO from Jim Hollingshead, who has led Insulet since 2022. In its announcement, Insulet said that Hollingshead and the company mutually agreed to part ways, effective immediately. A new free mobile game launched this week to make type 1 diabetes onboarding faster, easier and less overwhelming. It is called Level 1. It is a teaching game created by Level X, the studio behind Medical Games for Medical Professionals. I spoke to Level X CEO Sam Glasenberg recently. We're going to have him in an upcoming podcast episode. He said he created the game after his five year old daughter's diagnosis and said the experience was brutal. It took him a year to understand how to manage this disease. He wanted to build a game that could train your brain to do it in a matter of hours. The game has some big partners here beyond type 1 and breakthrough T1D play researchers at Carnegie Mellon say they have a big breakthrough with a 3D bioprinting technique. This method enables the precise printing of soft living cells and tissues. They say new possibility for studying disease and engineering therapies for conditions like type 1. For example, they say they have built a more complex vascularized tissue out of fully biologic materials to create a pancreatic like tissue. They say these models are fully biologic, which means cells function better. Another study showing the blood sugar benefit of walking after a meal. This study says that physical activity can facilitate glucose clearance from the bloodstream even without a robust insulin response. No high intensity exercise required here. Post prandial or post meal walking is accessible to a broad range of individuals. They say starting activity within 30 minutes after a meal is optimal. Dexcom is bringing back DexcomU for a fourth year. This is their name, image and license program for college athletes with diabetes. This time around they've got a nationwide open call for quote, passionate and inspiring college athletes. Now through May 23, athletes, coaches, friends and family members can nominate candidates through an online submission. We have that link in the show notes. Those selected, along with the eight returning athletes from last year will be invited to attend Dexcom U Signing Day Camp this summer hosted by Baltimore Ravens tight end Mark Andrews. And that's in the news. If you like it, please share it. I'm Stacey Sims. I'll see you back here soon. Until then, be be kind to yourself. Diabetes Connections is a production of Stacey Sims Media. All rights reserved. All wrongs avenged.